Abstract 4041: Translational assessment of triple combination with Tislelizumab (anti-PD-1), LBL-007 (anti-LAG-3) and &lt; for Surzebiclimab (anti-TIM-3) highlights its strong anti-tumor activity and &lt; for clinical potential in solid tumors such as HNSCC

Authors: Hengrui Zhu, Jinhui Zhang, Han Yan, Xiao Ding, Juan Yang, Yu Jiang, Minjuan Deng, Haoxuan Song, Fangfang Ping, Fuyun Sun, Xiaoyu Li, Lijie Zhang, Bin Jiang, Weiwei Song, Zhirong Shen, Wei Jin, Jiyuan Zhang, Yun Zhang

Published: 2024-03-22

DOI: 10.1158/1538-7445.am2024-4041

Source: Full article

Abstract 4041: Translational assessment of triple combination with Tislelizumab (anti-PD-1), LBL-007 (anti-LAG-3) and &amp;lt; for Surzebiclimab (anti-TIM-3) highlights its strong anti-tumor activity and &amp;lt; for clinical potential in solid tumors such as HNSCC

Abstract

Abstract 4041: Translational assessment of triple combination with Tislelizumab (anti-PD-1), LBL-007 (anti-LAG-3) and < for Surzebiclimab (anti-TIM-3) highlights its strong anti-tumor activity and < for clinical potential in solid tumors such as HNSCC